Rosacea Market Overview
The global Rosacea market size is estimated to reach $3.3 Billion in 2030 from $1.96 Billion in 2020, at a CAGR of 5.47% between 2020 and 2030. The demand for Rosacea from emerging Asian and Latin American countries is poised to increasing rapidly, in particular, from second half of forecast period, following the increasing awareness rapid penetration of topical antibiotics. Increasing prevalence of the condition and growing awareness and affordability driven by launch of new drug candidates and strong pipeline are poised to drive the market.
Rosacea is a chronic inflammatory skin disease with symptoms such as deep facial redness, spider veins (telangiectasia) and acne-like inflammatory lesions (papules and pustules). It may create psychosocial burdens, such as embarrassment, anxiety and low self-esteem that may adversely affect quality of life.
Rosacea is categorized into four sub-types:
Some of the major developments likely to impact the industry
Rosacea Market Analysis, 2021
Growing awareness about rosacea, increasing prevalence of the condition, changing lifestyles coupled with awareness programs and absence of treatment for rosacea are encouraging companies to invest significantly in R&D to develop products to gain from the huge unmet demand. Companies like Sol-Gel Technologies, Biowest Therapeutics, Maruho Co., Ltd, Amgen, Alfasigma, Biomemtix, Timber Pharmaceuticals, and others are focusing on constantly assessing diverse mechanism of actions to identify potential treatment options.
Rosacea is a chronic, inflammatory and vascular disorder affecting the face. Onset is usually after age 30 and typically begins as flushing and subtle redness on the cheeks, nose, chin or forehead. The characteristic skin lesions (erythema, visible blood vessels, papules and pustules) appear on the face and with progression of the disease, the redness becomes more persistent, blood vessels become visible and pimples often appear. In addition, burning, stinging, dry skin, plaques and skin thickening are other symptoms observed in the condition.
Rosacea is one of the most common conditions treated by dermatologists but the etiology of the condition is unknown. A family history of the disease is a risk factor, as is the very light skin phototype (Celtic skin type). The condition may be triggered from consumption of alcohol, spicy food, and changes in weather, exposure to sun or hot showers. Stinging, burning, sensitivity of the skin and inability to tolerate cosmetics are also common in rosacea. The condition has a strong impact on quality of life and can be associated with depressive symptoms.
Strong pipeline is of one of the market drivers of Rosacea market. Companies are focusing on launching new products based on significant opportunities for strong product positioning, focused primarily on novel delivery and high efficacy. Millennial and population aged between 30 and 50 remain major target group. Further, companies in the US and Europe increasingly rely on prescribing behaviour as focused guide for HCP targeting. Comparative pricing to other branded products, and ensuring broad access are among the key strategies opted by companies with planned therapeutic pipeline candidates.
Currently, 7 major prescription drugs are marketed for rosacea. A significant volume of patients switches or discontinue Rosacea therapy after first diagnosis. Further, there is no known cure for rosacea and treatment is aimed at alleviating the disorder's symptoms. Current treatment methods include topical formulations of antimicrobials such as metronidazole, clindamycin and ivermectin, azelaic acid or retinoids. Further, oral and topical antibiotics are also widely prescribed.
Different oral and topical medications are prescribed by patients to treat the signs and symptoms associated with Rosacea. Physicians often suggest antibiotics and other drug types. They also prescribe medical therapy specifically to control the redness. Bumps and pimples often receive initial treatment with oral and topical therapy to bring the condition under immediate control, followed by long-term use of an anti-inflammatory therapy alone to maintain remission.
The global Rosacea market is valued at $1,960 million in 2020. Further, over the forecast period to 2030, the market is poised to register 5.47% growth (Compounded Annual Growth Rate- CAGR) to reach $3,340 million in 2030. The major factors shaping up the demand outlook include increasing incidences of disease, launch of generics, and possible approval of VERED. On the other hand, low penetration rate in developing markets, low awareness in these markets, unknown etiology of the condition, and inadequate diagnosis coupled with low adherence are main market challenges.
The report analyses the global Rosacea market across drug types, route of administration and geographies. The drug types analysed in the report include Alpha agonists, Antibiotics, Azelic acid and others. Among types, antibiotics remain the dominant drug type with 67.8% market share. This is largely driven by prescriptions of oral and topical antibiotics and presence of a large number of products in the category.
In terms of route of administration, the market is categorized into oral and topical. Of these, topical dominated the industry in terms of market size with 70.8% market share. This is largely due to the limited side effects of topical compounds and patient willingness to opt for topical gel and foams compared to oral medication. However, for Phymatous Rosacea and Ocular Rosacea conditions, oral medication is largely prescribed.
Awareness campaigns and expansion into new markets coupled with increasing diagnosis of the disease are the main market drivers for Rosacea in developed countries in North America, and Europe. Among regions, North America remained the global markets with the US being the world’s largest country for rosacea treatment. The region accounted for 64.2% of global market demand, followed by Europe (21.4%). On the other hand, Asia Pacific is the fastest growing geography, forecast to register 6.3% CAGR over the forecast period. The fastest growth in China, India, Brazil, Eastern Europe and other countries is driven by launch of new products and increased diagnosis in the second half of forecast period.
In terms of companies, the current market landscape is characterized by presence of a few players such as Galderma, Leo Pharma, Aclaris, and Vyne Therapeutics. In addition, companies marketing generics also have significant presence in the industry.
Rosacea Companies included in the research-
Bayer Schering AG
Bausch Health Companies Inc.
Rosacea Market Trends- Combination topical therapy continues to gain traction
While single agent topical therapy is among the leading treatment option preferred for rosacea patients, an increasing trend towards use of combination topical therapy is being observed. Metronidazole and azelaic acid are among the most prescribed combination for the condition. Combination of topical and oral medication such as Ivermectin and oral doxycycline is also being assessed.
According to National Rosacea Society, fixed centrofacial erythema with periodic intensification, and phymatous changes remain the primary phenotypes while papules and pustules, flushing, telangiectasia, and ocular manifestations can also co-occur with the primary symptoms. Further, secondary signs and symptoms such as burning or stinging sensations, facial edema, and a dry appearance of central facial skin can be observed among patients.
As Rosacea is an evolving condition, physicians consider all clinical signs and symptoms of rosacea observed in an individual patient, identifying those signs and symptoms that change over time, and accordingly suggest the most suitable combination therapy applicable to target all rosacea symptoms.
Rosacea Market Drivers- Rosacea has Strong Unmet Demand
Rosacea presents significant unmet demand potential. As the approved drugs do not treat the condition but instead treats the symptoms and signs, there exists huge unmet market demand. Further, high rate of treatment discontinuation coupled with side effects of long term usage restrict market size growth.
Pharmaceutical companies and institutes are investing in developing drugs that has minimal side effects and has more efficacy such as extended release and microencapsulation technology.
Rosacea Market Report Segmentation-
Rosacea Pipeline Products (Phase and Phase 3)
Zilxi is the latest approved drug in the rosacea treatment market, with the minocycline drug being approved in 2020. It is the first new option for papulopustular rosacea in 5+ years and accordingly, presents significant demand potential. Marketed by Vyne Therapeutics Inc., the company made the drug available in pharmacies from October 2020 in the US. ZILXI (minocycline) topical foam, 1.5% is a topical form of the antibiotic minocycline. We anticipate the product to generate around $200 million by 2030 from initial sales of around $23 million in 2021. Though it will erode into the profits of competing products, we estimate the product to generate additional revenues to the industry with increased number of prescriptions.
1. TABLE OF CONTENTS 2
1.1 List of Tables 6
1.2 List of Figures 7
2. EXECUTIVE SUMMARY 8
2.1 Summary 8
2.1.1 Overview 8
2.1.2 Market Sales 10
2.1.3 Some of the major developments likely to impact the industry 11
2.2 Rosacea Industry Outlook, 2020 – 2030 12
2.3 Abbreviations 13
3. INTRODUCTION TO ROSACEA MARKET 14
3.1 Market Segments - Types, Applications, and Countries 14
3.2 Report Guide 15
3.3 Research Methodology 16
4. MACROECONOMIC & DEMOGRAPHIC OUTLOOK 17
4.1 GDP Outlook, 2020 – 2030 17
4.2 Population Outlook of Select Countries, 2020 – 2030 18
5. OVERVIEW OF THE ROSACEA MARKET 19
5.1 Industry Panorama 19
5.2 Major Companies 21
5.3 Market Trends 21
5.3.1 Impact of generics on global market size 22
5.3.2 Small companies offer potential investment and partnership opportunities 22
5.3.3 Combination topical therapy continues to gain traction 23
5.3.4 Rosacea has Strong Unmet Demand 23
5.3.5 Unknown etiology poses challenges for new product development 23
5.3.6 COVID-19 mask wearing worsens rosacea symptoms 24
5.3.7 Inadequate and difficult diagnosis challenges prevalence estimation in developing countries 24
5.3.8 Increase in disease prevalence 24
5.3.9 Off-label usage of drugs poses challenges 24
5.3.10 Increasing global Healthcare Expenditure worldwide is among the main market drivers 25
5.4 Leading Routes of Administration 26
5.4.1 Orals 27
5.4.2 Topical 28
5.5 Dominant Drug Classes 29
5.6 Regional Analysis 50
6. GLOBAL OUTLOOK ACROSS COVID-19 SCENARIOS 51
6.1 Post COVID Scenario 51
6.2 Pre COVID Scenario 52
7. NORTH AMERICA ROSACEA MARKET ANALYSIS 53
7.1 Overview 53
7.1.1 The US dominates the North American Rosacea Market 54
7.2 Market Outlook by Country 55
7.2.1 The US 55
7.2.2 Other North America 56
8. EUROPE ROSACEA MARKET ANALYSIS 57
8.1 Overview 57
8.1.1 Germany dominates the European Rosacea Market 58
8.2 Market Outlook by Country 59
8.2.1 Germany 59
8.2.2 United Kingdom 60
8.2.3 France 61
8.2.4 Spain 62
8.2.5 Italy 63
8.2.6 Other Europe 64
9. ASIA PACIFIC ROSACEA MARKET ANALYSIS 65
9.1 Overview 65
9.1.1 Japan dominates the Asia Pacific Rosacea Market 66
9.2 Market Outlook by Country 67
9.2.1 Japan 67
9.2.2 Other Asia Pacific 68
10. REST OF WORLD ROSACEA MARKET ANALYSIS 69
10.1 Overview 69
11. COMPETITIVE LANDSCAPE 71
11.1 Vyne Therapeutics Inc 71
11.1.1 Overview 71
11.1.2 SWOT Analysis 72
11.2 Bausch Health Companies Inc 74
11.2.1 Overview 74
11.2.2 SWOT Analysis 76
11.2.3 Key Financials 77
11.3 Bayer Schering AG 80
11.3.1 Overview 80
11.3.2 SWOT Analysis 81
11.4 Allergan plc 83
11.4.1 Overview 83
11.4.2 SWOT Analysis 84
11.4.3 Key Financials 86
11.5 Sol-Gel Technologies 89
11.5.1 Overview 89
11.5.2 SWOT Analysis 90
11.5.3 Key Financials 92
12. APPENDIX 95
12.1 About USD Analytics 95
12.2 Sources and Research Methodology 95
12.3 Copyright and Disclaimer 96